



Suven at Alzheimer's Association International Conference (AAIC) in Chicago.

HYDERABAD, INDIA (July 23, 2018) – Suven is exhibiting and presenting several exciting new results and data presentations from Suven's portfolio of investigational neuroscience **New Chemical Entities (NCEs)** which are being presented at **Alzheimer's Association International Conference (AAIC)** being held in Chicago, USA starting July 22nd to 26th, 2018.

AAIC® is the largest and most influential international meeting dedicated to advancing dementia science. Each year, AAIC convenes the world's leading basic science and clinical researchers, next generation investigators, clinicians and the care research community to share research discoveries that will lead to methods of prevention and treatment, and improvements in diagnosis for Alzheimer's disease.

Alzheimer's disease is one of the scourges of modern day health care. **Alzheimer's is not just a memory loss as everyone thinks but Alzheimer's kills.** Current Alzheimer's treatments cannot stop Alzheimer's from progressing, they can temporarily slow the worsening of dementia symptoms and improve quality of life. Today, there is a worldwide effort under way to find better ways to treat the disease, delay its onset, and prevent it from developing and this is where **Suven is focusing on developing drugs for the treatment of this debilitating disease.**

Suven has excellent portfolio of new molecules through 4 mechanisms of action using 5-HT₆, 5-HT₄, H₃ receptors and M1PAM for the symptomatic treatment of cognitive impairment in Alzheimer's disease but also possibly useful in reducing the disease progression. Suven scientists are presenting pre-clinical and clinical data on these molecule and other NCEs on memory related disorders.

About Suven Life Sciences

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets. Suven has 4 clinical stage compounds, a Phase 2 undergoing SUVN-502; Phase 2 ready SUVN-G3031 and Phase1completed SUVN-D4010 for Alzheimer's disease and Schizophrenia and sleep disorders. SUVN-911 is the 4th developmental molecule from Suven's drug discovery pipeline for Major Depressive Disorder (MDD) which is undergoing Phase 1 clinical trial in USA and phase1 ready SUVN-l6107. In addition the Company has nine (9) internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.

For more information please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

CIN: L24110TG1989PLC009713

6/F, Serene Chambers, Rd#7, Banjara Hills Hyderabad 500034, India
Tel: 9140 2354 1142 Fax: 9140 2354 1152 Email: info@suven.com